Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell tags : Potential save search
Analyses of Kite’s Yescarta® CAR T-Cell Therapy Support Curative Potential in Patients With Non-Hodgkin Lymphomas
Published: 2023-12-12 (Crawled : 07:00) - biospace.com/
GILD | $67.75 -0.47% -0.46% 5M
|
Health Technology
|
| O: 0.86%
H: 0.49%
C: 0.05%
yescarta t-cell lymphomas potential therapy
Actinium Presents Preclinical Data at SITC Demonstrating Actimab-A's Potential to Restore T Cell Immunity in the Solid Tumor Microenvironment Supporting Immunotherapy Combinations
Published: 2023-11-06 (Crawled : 12:30) - prnewswire.com
ATNM | $8.44 -6.22% 0.0% 260K
|
Health Technology
|
| O: 0.63%
H: 4.38%
C: -5.01%
cell tumor preclinical immunotherapy potential
Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases
Published: 2023-11-01 (Crawled : 23:00) - globenewswire.com
CRVS | $1.47 -3.92% -1.96% 69K
|
Health Technology
|
| O: 5.93%
H: 5.59%
C: -2.4%
publication pharmaceuticals preclinical potential
Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023
Published: 2023-10-31 (Crawled : 13:00) - prnewswire.com
COEP | $0.3749 -10.44% -10.13% 420K
|
|
| O: -1.12%
H: 0.0%
C: -8.71%
cd20 her2 tumor research therapeutics potential growth
EvolveImmune Therapeutics to Present New Preclinical and Translational Data Highlighting Precision Medicine Potential of its Novel Costimulatory T Cell Engager Platform at 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Published: 2023-10-18 (Crawled : 15:00) - biospace.com/
IMUN | $0.093 214.52% 1.8K
|
Manufacturing
| Email alert
Add to watchlist
cancer cell preclinical immunotherapy meeting therapeutics potential platform
IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma
Published: 2023-10-12 (Crawled : 12:00) - globenewswire.com
INAB | $1.02 -8.11% -7.77% 350K
|
|
| O: 1.0%
H: 0.0%
C: -5.94%
inb-100 inb-400 cell treatment trial potential therapy glioblastoma
Coya Therapeutics Successfully Engineers Regulatory T Cell (Treg) Derived Exosomes with CTLA-4 Protein to Selectively Target Immune Cells with Potential to Deliver Targeted Therapies Across Multiple Diseases
Published: 2023-09-07 (Crawled : 14:30) - biospace.com/
COYA | $8.37 -7.21% -8.67% 75K
|
|
| O: 0.93%
H: 19.86%
C: 11.09%
cell protein therapeutics potential
Coya Therapeutics Announces Publication of Potential Novel Blood Biomarker Data in Amyotrophic Lateral Sclerosis (ALS) Patients That Accurately Reflect Therapeutic Responses When Treated with Regulatory T Cell (Treg) Enhancing Therapies
Published: 2023-08-31 (Crawled : 14:30) - biospace.com/
COYA | $8.37 -7.21% -8.67% 75K
|
|
| O: -0.85%
H: 3.45%
C: 1.44%
biomarker publication sclerosis cell blood therapeutics potential
CPI-818 Data Highlights Potential for ITK Inhibition as a New Immunotherapy Approach for the Treatment of T Cell Lymphoma
Published: 2023-04-03 (Crawled : 14:20) - biospace.com/
CRVS | $1.47 -3.92% -1.96% 69K
|
Health Technology
|
| O: -3.3%
H: 13.64%
C: 13.08%
cpi-818 cell treatment immunotherapy potential
EvolveImmune Therapeutics Presents New Preclinical Data Demonstrating Improved Anti-Tumor Potential of Novel Costimulatory T Cell Engager Platform at Festival of Biologics Immunotherapy World Congress
Published: 2023-03-22 (Crawled : 13:00) - biospace.com/
IMUN | $0.093 214.52% 1.8K
|
Manufacturing
| Email alert
Add to watchlist
cell preclinical immunotherapy therapeutics potential platform
Coya Therapeutics, Inc. Announces Preclinical Data Supporting the Role of Expanded Regulatory T Cells (Tregs) as Potential Disease-Modifying Treatment in an Animal Model of Alzheimer’s Disease (AD)
Published: 2023-01-26 (Crawled : 15:00) - biospace.com/
COYA | $8.37 -7.21% -8.67% 75K
|
|
| O: -3.77%
H: 3.69%
C: 0.22%
treatment disease preclinical animal alzheimer’s potential
Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer
Published: 2023-01-25 (Crawled : 14:00) - allogene.com
ALLO | $3.55 -6.58% -7.19% 1.6M
|
Health Technology
|
| O: -2.14%
H: 4.18%
C: 2.83%
lung research preclinical therapeutics potential cancer
Bellicum Announces Presentation by UNC at ASH 2022 on Potential Abrogation of iC9 CAR T-Cell Toxicities with Rimiducid
Published: 2022-12-11 (Crawled : 16:20) - globenewswire.com
BLCM | $0.0748 381.28% 6.1K
|
Health Technology
| Email alert
Add to watchlist
t-cell presentation potential
SQZ Biotechnologies Presents Preclinical SQZ® TIL Data Supporting Potential Ability of mRNA-Driven IL-2 and IL-12 Expression to Eliminate Need for Toxic Preconditioning and Systemic IL-2 Administration for Certain T Cell Therapies
Published: 2022-09-12 (Crawled : 12:00) - biospace.com/
SQZ | $0.435 0.0% 30M
|
Health Technology
|
| O: 2.03%
H: 4.32%
C: 0.66%
il-12 sqz preclinical potential
Cellectis Publishes Article in Nature Communications Unveiling Novel Immune-Evasive Universal Allogeneic CAR T-cells with Potential for Improved Persistence
Published: 2022-06-30 (Crawled : 10:00) - globenewswire.com
CLLS | $2.61 -2.97% -3.86% 42K
|
Health Technology
|
| O: -1.74%
H: 6.38%
C: 0.35%
communications potential
Adicet Presents Preclinical Data at the ISCT Annual Meeting Highlighting Potential Advantages of the Non-Gene-Edited Approach for its Investigational Allogeneic Gamma Delta CAR T Cell Therapy Targeting CD20 for B Cell Malignancies
Published: 2022-05-05 (Crawled : 12:00) - biospace.com/
ACET | $2.2 1.85% 2.26% 450K
|
Health Technology
|
| O: 0.72%
H: 3.56%
C: -0.84%
cd20 preclinical potential therapy pre-clinical
Mustang Bio to Host Key Opinion Leader Webinar on MB-106, a Potential Treatment for B-Cell Non Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
Published: 2021-12-09 (Crawled : 14:00) - globenewswire.com
MBIO | $0.375 -26.18% -36.34% 700K
|
Health Technology
|
| O: 2.88%
H: 1.87%
C: -3.27%
FBIO | $1.82 1.11% 0.55% 340K
|
Health Technology
|
| O: 4.85%
H: 0.0%
C: 0.0%
mb-106 treatment leukemia potential lymphomas t-cell
Greenwich LifeSciences Announces Presentation of 5 Year Data for GP2 Phase IIb Clinical Trial, Revealing Potential For New T Cell Platform Technology
Published: 2021-12-09 (Crawled : 12:30) - biospace.com/
GLSI | $14.26 -8.88% -9.79% 64K
|
Health Technology
|
| O: 4.11%
H: 0.9%
C: -12.42%
technology trial presentation potential platform t-cell
P-MUC1C-ALLO1: A Fully Allogeneic Stem Cell Memory T Cell (TSCM) CAR-T Therapy with Broad Potential in Solid Tumor
Published: 2021-11-16 (Crawled : 01:00) - poseida.com
PSTX | $2.43 -10.99% -12.35% 520K
|
Health Technology
|
| O: -1.39%
H: 0.0%
C: 0.0%
stem cell potential therapy car-t t-cell
Nurix Therapeutics Announces IND clearance for DeTIL-0255, a drug-enhanced autologous T cell therapy for the potential treatment of a variety of solid tumors
Published: 2021-11-12 (Crawled : 13:00) - biospace.com/
NRIX 2 d | $15.46 -7.65% -8.28% 2M
|
Health Technology
|
| O: -1.54%
H: 0.0%
C: 0.0%
treatment solid tumors potential therapy drug clearance t-cell
Gainers vs Losers
| 45% | 55% |
Top 10 Gainers
KAVL | $6.3 135.96% 57.45% 44M
|
Wholesale Trade
PXMD | $0.74 79.7% 44.16% 4.5M
|
Health Technology
DYNT | $0.3704 -5.27% 43.09% 5.5M
|
Health Technology
LGVN P 3 d | $2.93 73.37% 42.52% 56M
|
HUBC | $1.95 50.0% 32.99% 73M
|
n/a
SPCB | $0.4004 45.07% 31.75% 130M
|
Electronic Technology
ONVO | $1.35 33.65% 24.62% 53M
|
Health Technology
OMQS | $0.7038 35.35% 24.3% 3.5M
|
Professional, Scientific, and T...
SNPO | $10.54 29.48% 22.88% 3.9M
|
EEIQ | $1.16 27.46% 20.86% 6.9K
|
Educational Services
Your saved searches
Save your searches and get alerts when important news are released.